A new license agreement between Tolero Pharmaceuticals Inc., of Salt Lake City, and MannKind Corp., of Valencia, Calif., will grant Tolero exclusive worldwide rights to some of MannKind's Bruton's tyrosine kinase (Btk) compounds, which have potential for hematological malignancies and inflammatory disease. Read More
Last week was a busy one for Boulder, Colo.-based miRagen Therapeutics Inc. On Monday, the company announced it had completed a Series B round of $20 million. (See BioWorld Today, April 24, 2012.) Read More
WASHINGTON – Does the U.S. government's funding of early drug research entitle it to a say in drug pricing discussions? That question is at the center of a debate over whether the current government-academia-industry research model is out of balance. Read More
• Altor BioScience Corp., of Miramar, Fla., and the Melanoma Research Alliance (MRA) will jointly sponsor a University of Washington study of Altor's IL-15 superagonist, ALT-803, against metastatic melanoma. MRA selected the project under its Academic-Industry Partnership grant program. Read More
• Hemispherx Biopharma Inc., of Philadelphia, said Ampligen (rintatolimod), an experimental immunotherapeutic, was administered intranasally in conjunction with FluMist (influenza vaccine live, intranasal) to healthy volunteers in a study at the University of Alabama at Birmingham. Read More
• Merck & Co. Inc., of Whitehouse Station, N.J., said the District Court for the District of New Jersey ruled in its favor in two jointly related patent infringement suits against Mylan Pharmaceuticals Inc., of Pittsburgh, upholding Merck's patent on Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin). Read More
